Biogen Inc (BIIB)
157.84
-0.17
(-0.11%)
USD |
NASDAQ |
Nov 22, 16:00
158.00
+0.16
(+0.10%)
After-Hours: 20:00
Biogen Revenue (TTM): 9.608B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 9.608B |
| June 30, 2024 | 9.672B |
| March 31, 2024 | 9.663B |
| December 31, 2023 | 9.836B |
| September 30, 2023 | 9.993B |
| June 30, 2023 | 9.972B |
| March 31, 2023 | 10.10B |
| December 31, 2022 | 10.17B |
| September 30, 2022 | 10.36B |
| June 30, 2022 | 10.63B |
| March 31, 2022 | 10.82B |
| December 31, 2021 | 10.98B |
| September 30, 2021 | 11.10B |
| June 30, 2021 | 11.70B |
| March 31, 2021 | 12.60B |
| December 31, 2020 | 13.44B |
| September 30, 2020 | 14.26B |
| June 30, 2020 | 14.49B |
| March 31, 2020 | 14.42B |
| December 31, 2019 | 14.38B |
| September 30, 2019 | 14.23B |
| June 30, 2019 | 14.07B |
| March 31, 2019 | 13.81B |
| December 31, 2018 | 13.45B |
| September 30, 2018 | 13.23B |
| Date | Value |
|---|---|
| June 30, 2018 | 12.87B |
| March 31, 2018 | 12.59B |
| December 31, 2017 | 12.27B |
| September 30, 2017 | 11.84B |
| June 30, 2017 | 11.72B |
| March 31, 2017 | 11.53B |
| December 31, 2016 | 11.45B |
| September 30, 2016 | 11.42B |
| June 30, 2016 | 11.24B |
| March 31, 2016 | 10.94B |
| December 31, 2015 | 10.76B |
| September 30, 2015 | 10.57B |
| June 30, 2015 | 10.30B |
| March 31, 2015 | 10.13B |
| December 31, 2014 | 9.703B |
| September 30, 2014 | 9.028B |
| June 30, 2014 | 8.345B |
| March 31, 2014 | 7.647B |
| December 31, 2013 | 6.932B |
| September 30, 2013 | 6.384B |
| June 30, 2013 | 5.942B |
| March 31, 2013 | 5.640B |
| December 31, 2012 | 5.516B |
| September 30, 2012 | 6.164B |
| June 30, 2012 | 5.822B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
9.608B
Minimum
Sep 2024
14.49B
Maximum
Jun 2020
11.41B
Average
10.73B
Median
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 40.86B |
| Sage Therapeutics Inc | 106.40M |
| Pfizer Inc | 59.37B |
| Amgen Inc | 32.53B |
| Ionis Pharmaceuticals Inc | 803.07M |